KPRESS MAIL NO. EV335394085US

07-02.04

642	

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

		i/.
Application Member	09/593,793	
Filing Date	June 13, 2000	
First Named Inventor	Jiangchun Xu	JUL 0 8 2004
Art Unit	1642	
Examiner Name	David J. Blanchard	TECH CENTER 1000/2000
Attorney Docket No.	210121.427C15	ARMEN SAME

ENCLOSURES (check all that apply)							
Fee Transmitta Fee Attach Amendment/Re After Final Affidavits/c Extension of Texpress Abance Request Sixth Supplem Information Dis Statement; For Statement; For Certified Copy Document(s) Response to Medical and Completed Response to Medical an	al Form ned esponse declaration(s) ime Request donment ental sclosure rm PTO-1449 nces of Priority dissing Parts R. 1.52 or 1.53		Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund		CD(s), Number of CD(s) After Allowance Communication to Technology Center (TC)' Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):		
Remarks		<u> </u>	· · · · · · · · · · · · · · · · · · ·	l —			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
		undley, Ph.D., Patent Agent		Customer Number 00500			
Signature							
Date June 30, 2004							
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.							
Typed or printed name							
Signature				Dat	e:		
This collection of information is required by 37 CFR 1.5. Ti			information is required to obtain or retain a benefit	by the	public which is to file (and by the LISPTO to		

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



JUL 0 8 2004

EXPRESS MAIL NO. EV335394085US



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Jiangchun Xu et al.

Application No.

09/593,793

Filed

June 13, 2000

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF PROSTATE CANCER

Examiner

: David J. Blanchard

Art Unit

: 1642

Docket No.

210121.427C15

Date

: June 30, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 CFR 1.98, are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We hereby certify that each of the references set forth on the attached form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

Please acknowledge receipt of this Sixth Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Jeffrey Hundley, Ph.D., Patent Agent

Registration No. 42,676

JEH:ljt

Enclosures:

Postcard Transmittal Form Form PTO-1449 Cited References (5)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\494462

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Aspinall, J.O. et al., "Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues," <i>Journal of Urology 154</i> : 622-628, August 1996.
	AQ	Fannon, M.R., "Gene expression in normal and disease states – identification of therapeutic targets," <i>Trends in Biotechnology 14</i> : 294-298, August 1996.
	AR	Garde, S.V. et al., "Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)," <i>Cancer Letters</i> 78: 11-17, 1994.
•		GenBank Database, Accession No. AA112574, May 29, 2003.
		Murphy, G. et al., "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients," <i>Anticancer Research</i> 15: 1473-1480, 1995.

* EXAMINER:

EXAMINER

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

DATE CONSIDERED